Skip to main content

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression. The hyperthyroid patients in the TED studies showed similar response rates of thyroid hormone normalization to those seen in the batoclimab Phase 2 study in Graves’ disease Immunovant remains focused on rapid advancement of IMVT-1402 in multiple indicationsDURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases,...

Continue reading

Futu Announces Cash Dividend

HONG KONG, April 02, 2026 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (Nasdaq: FUTU), a leading tech-driven online brokerage and wealth management platform, today announced that its board of directors approved a cash dividend of US$0.325 per ordinary share, or US$2.6 per American Depositary Share (“ADS”), payable in U.S. dollars (the “Dividend”) to holders of ordinary shares and holders of ADSs of record as of the close of business on April 16, 2026, New York time. The aggregate amount of the Dividend will be approximately US$365 million. The Dividend to be paid to the Company’s ADS holders through the depositary bank will be subject to the terms of the deposit agreement. The payment date is expected to be on or around April 29, 2026 for holders of ordinary shares and holders of ADSs. About Futu Holdings Limited Futu...

Continue reading

Top Ships Announces Filing of 2025 Annual Report on Form 20-F

ATHENS, Greece, April 02, 2026 (GLOBE NEWSWIRE) — TOP Ships Inc. (the “Company”), an international owner and operator of modern, fuel efficient “ECO” tanker vessels, announced today that its annual report on Form 20-F for the year ended December 31, 2025 (the “Annual Report”) has been filed with the U.S. Securities and Exchange Commission (the “Commission”). The Annual Report may be accessed through the Company’s website, www.topships.org, or on the website of the Commission, www.sec.gov. About the Company TOP Ships Inc. is an international owner and operator of ocean-going vessels focusing on modern, fuel-efficient eco tanker vessels transporting crude oil, petroleum products (clean and dirty) and bulk liquid chemicals. For more information about TOP Ships Inc., visit its website: www.topships.org. Cautionary Note Regarding...

Continue reading

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026DURHAM, N.C., April 02, 2026 (GLOBE NEWSWIRE) — Priovant today announced a new Phase 2b/3 clinical program...

Continue reading

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the fourth indication in brepocitinib’s expanding late-stage development program Multiple lines of evidence, including strong mechanistic rationale and clinically meaningful results in an investigator-initiated placebo-controlled study of brepocitinib in LPP, support rapid development of brepocitinib in this indication A seamless Phase 2b/3 potentially registrational trial of brepocitinib in LPP enrolled its first subjects in March 2026 Immunovant’s Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint;...

Continue reading

Solvac publishes its 2025 Annual Report

Brussels, 2 April 2026 – 10.30 am CET  Solvac has released its 2025 Annual Report today. This document includes, as already communicated on March 6, 2026, the management report, the financial statements and the corporate governance declaration for the 2025 financial year. The report also presents Solvac’s purpose, clarifies its mission and outlines its vision. The 2025 Annual Report, including the ESEF version, is available on Solvac’s website in French and Dutch.   Solvac is a public limited company under Belgian law founded in 1983 and listed on the Euronext Brussels stock exchange under the ISIN code BE0003545531 (SOLV). Its assets consist exclusively of a stake of more than 30% in the capital of Solvay SA and in the capital of Syensqo SA. Its titles are exclusively nominative. They may be held freely by individuals or, with the...

Continue reading

Endeavour To Announce Its Q1 2026 Results On 30 April 2026

         ENDEAVOUR TO ANNOUNCE ITS Q1 2026 RESULTS ON 30 APRIL 2026 London, 2 April 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) expects to release its Q1 2026 financial results on Thursday 30 April 2026, before the LSE market open. Management will host a conference call and webcast on the same day, Thursday 30 April, at 8:30 am EST/ 1:30 pm BST to discuss the Company’s financial results. The conference call and webcast are scheduled at: 5:30am in Vancouver 8:30am in Toronto and New York Notice of Results1:30pm in London 9:30pm in Hong Kong and Perth The webcast can be accessed through the following link: https://edge.media-server.com/mmc/p/ftcspd85 Click here to add a Webcast reminder to your Outlook Calendar. Analysts and investors are invited to participate and ask questions by registering for the conference call...

Continue reading

Share Buyback Transaction Details March 26 – April 1, 2026

PRESS RELEASE                                         Share Buyback Transaction Details March 26 – April 1, 2026 Alphen aan den Rijn – April 2, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 105,281 of its own ordinary shares in the period from March 26, 2026, up to and including April 1, 2026, for €6.7 million and at an average share price of €63.67. These repurchases are part of the share buyback program announced on February 25, 2026, under which we intend to repurchase shares for up to €500 million during 2026. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2026Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2026...

Continue reading

Programme for the issuance of Collateralised ETP Securities

 2 April 2026 WisdomTree Multi Asset Issuer Public Limited CompanyProgramme for the issuance of Collateralised ETP Securities Consolidations of the Collateralised ETP Securities of the following classes:WisdomTree Silver 3x Daily ShortWisdomTree EURO STOXX 50 3x Daily ShortWisdomTree DAX 3x Daily ShortWisdomTree Brent Crude Oil 3x Daily ShortWisdomTree Copper 3x Daily Short Terms used in this announcement and not otherwise defined bear the same meanings as where used in the prospectus of the Issuer dated 25 September 2025 for the programme for the issuance of Collateralised ETP Securities. Introduction WisdomTree Multi Asset Issuer Public Limited Company (the “Issuer”) announces that pursuant to Condition 17.2, it will be effecting consolidations (the “Consolidations”) at the close of business on 17 April 2026 of the following classes...

Continue reading

Municipality Finance issues EUR 50 million zero coupon notes under its MTN programme

Municipality Finance PlcStock exchange release 2 April 2026 at 10:00 am (EEST) Municipality Finance issues EUR 50 million zero coupon notes under its MTN programme Municipality Finance Plc issues EUR 50 million zero coupon notes on 7 April 2026. The maturity date of the notes is 7 April 2051. MuniFin has a right, but no obligation, to redeem the notes early on 7 April 2036. The notes are issued under MuniFin’s EUR 50 billion programme for the issuance of debt instruments. The offering circular and the final terms of the notes are available in English on the company’s website at https://www.kuntarahoitus.fi/en/for-investors. MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 7 April 2026. DZ BANK AG Deutsche Zentral-Genossenschaftsbank,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.